Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 2001

Syringe, pen, inhaler - the evolution of insulin therapy.

Igor Alexander Harsch, Eckhart Georg Hahn, Peter Christopher Konturek

Med Sci Monit 2001; 7(4): RA833-836 :: ID: 421063

Abstract

The therapy with inhalable insulin can be expected to change the presentconcepts and the market of subcutaneous insulin dramatically within the next years. Several companiesare currently developing formulations of inhalable insulin. In the most advanced concept, insulin isdelivered as a dry-powder insulin formulation via a special aerosol device system. The phase III studiesevaluating the efficiency of the inhaled insulin are already on their way. The recent phase II studieshave shown, that the lung is capable of absorbing new insulin formulation in a dose-dependent and reproduciblemanner. However, a relatively small number of diabetic patients have been included in these studies,yet. The therapeutic efficacy and safety of the inhaled insulin is comparable to that of the usual subcutaneousinsulin treatment regimens. The most important advantage of the new therapy is the enhanced therapeuticcomfort of the patient who does not need to inject insulin for meal time glucose control. Generally,in terms of glycemic control, inhalable insulin offers no advantages in type 1 diabetics in comparisonto an intensified conventional insulin therapy. However, before a large-scale marketing, several openquestions have to be carefully investigated, the most important being the possible long-term effectsof insulin inhalation for the lung, since insulin is known to have growth-promoting properties. Thereis still no available clinical data concerning the efficiency of the inhaled insulin in patients withpulmonary diseases which may cause problems in absorption of inhaled insulin due to the smaller cumulativealveolar surface. In smokers without pulmonary disease seems the inhaled insulin to act stronger andfaster. Since therapy with inhalable insulin requires larger doses of insulin in comparison to subcutaneousinsulin to achieve the same systemic effect, the costs of this therapy need to be clarified, too.

Keywords: inhaled insulin, lung function, fibrogenesis, Diabetes Mellitus, alveoles

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750